International Biotechnology Trust’s CRISPR Therapeutics CRSP Stock Holding History

International Biotechnology Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.86M	Buy	+63,000	New	+$3.25M	0.96%	32
2023 Q2	–	Sell	-34,200	Closed	-$1.55M	–	68
2023 Q1	$1.55M	Hold	34,200	–	–	0.43%	46
2022 Q4	$1.39M	Hold	34,200	–	–	0.43%	42
2022 Q3	$2.23M	Buy	34,200 +32,122	+1,546%	+$2.33M	0.72%	40
2022 Q2	$34.2K	Buy	+2,078	New	+$122K	0.36%	52
2022 Q1	–	Sell	-108,200	Closed	-$8.19M	–	74
2021 Q4	$8.19M	Buy	+108,200	New	+$9.45M	1.83%	21
2021 Q2	–	Sell	-22,000	Closed	-$2.68M	–	68
2021 Q1	$2.68M	Hold	22,000	–	–	0.71%	29
2020 Q4	$3.37M	Hold	22,000	–	–	0.92%	24
2020 Q3	$1.84M	Hold	22,000	–	–	0.59%	30
2020 Q2	$1.65M	Hold	22,000	–	–	0.55%	30
2020 Q1	$930K	Hold	22,000	–	–	0.42%	36
2019 Q4	$1.34M	Buy	+22,000	New	+$1.2M	0.48%	44

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

International Biotechnology Trust's CRSP Position: Q3 2023 in Review

International Biotechnology Trust opened a new position in CRISPR Therapeutics (CRSP) in Q3 2023: 63,000 shares worth $2.86M. The stake represents 0.96% of the portfolio and ranks #32 among its holdings. This is a return to the name: International Biotechnology Trust previously reported a position in CRSP as recently as Q1 2023.

International Biotechnology Trust first reported a position in CRSP in Q4 2019 and has held it in 12 quarters since. The position peaked at $8.19M in Q4 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

International Biotechnology Trust held 63,000 shares of CRISPR Therapeutics worth $2.86M as of Q3 2023.
CRISPR Therapeutics was a new International Biotechnology Trust position in Q3 2023.
CRISPR Therapeutics made up 0.96% of International Biotechnology Trust's portfolio in Q3 2023, its #32 holding.
International Biotechnology Trust first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 12 quarters since.
International Biotechnology Trust's CRISPR Therapeutics position peaked at $8.19M in Q4 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.